Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29204433 | 0.84 | SIGMAR1 (0.60) | SIGMAR1AVPR1AOPRD1 | |
| SCHEMBL6919513 | 0.81 | SIGMAR1 (0.57) | SIGMAR1OPRD1 | |
| SCHEMBL9615977 | 0.80 | SIGMAR1 (0.54) | SIGMAR1AVPR1AOPRD1 | |
| SCHEMBL15963361 | 0.80 | SIGMAR1 (0.59) | SIGMAR1AVPR1AOPRD1 | |
| SCHEMBL12183893 | 0.80 | SIGMAR1 (0.56) | SIGMAR1AVPR1AOPRD1 | |
| SCHEMBL24507144 | 0.80 | SIGMAR1 (0.59) | SIGMAR1AVPR1AOPRD1 | |
| SCHEMBL8010724 | 0.79 | SIGMAR1 (0.66) | SIGMAR1 | |
| SCHEMBL29990866 | 0.78 | AVPR1A (0.59) | SIGMAR1AVPR1A | |
| SCHEMBL6993813 | 0.78 | AVPR1A (0.59) | SIGMAR1AVPR1A | |
| SCHEMBL1222056 | 0.78 | AVPR1A (0.59) | SIGMAR1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3932914-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-2927214-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | AVPR1A, AVPR2, OXTR | SIGMAR1 53/4885AVPR1A 1/4885OPRD1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.